Working… Menu

A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP (PrEPVacc)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04066881
Recruitment Status : Not yet recruiting
First Posted : August 26, 2019
Last Update Posted : August 26, 2019
Imperial College London
University College, London
International AIDS Vaccine Initiative
EuroVacc Foundation
Medical Research Council, South Africa
National Institute for Medical Research, Tanzania
Muhimbili University of Health and Allied Sciences
Instituto Nacional de Saúde, Mozambique
Ludwig-Maximilians - University of Munich
King's College London
Centre Hospitalier Universitaire Vaudois
Karolinska Institutet
Gilead Sciences
Information provided by (Responsible Party):
Prof Pontiano Kaleebu, MRC/UVRI and LSHTM Uganda Research Unit

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : March 2023